Last reviewed · How we verify
Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis
Approved treatments
- Velsipity · Pfizer Inc.
Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs.
Clinical guidelines
- FDA label — maintenance
VELSIPITY is indicated for the maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis. - FDA label — maintenance
VELSIPITY is indicated for the maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis patent landscape — cliff calendar, originator estates, attackable patents
- Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis treatment landscape brief
- Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis treatment updates RSS
Frequently asked questions about Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis
What drugs treat Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis?
Tracked treatments include Velsipity.
What is the treatment for Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis?
Standard treatment for Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis includes Velsipity. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis?
FDA label publishes guidelines for Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis. 2 guideline references tracked.
Related
- Treatment landscape: Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis patent cliff · Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis CI report
- Treatment: Velsipity · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing